PEG修饰蛋白定制合成-西安齐岳生物提供

聚乙二醇（PEG）修饰是生物医药领域优化蛋白类药物、功能蛋白理化性质与体内药效的核心技术手段，通过PEG链与蛋白分子的共价偶联，可显著延长蛋白体内半衰期、降低免疫原性、提升水溶性与结构稳定性，同时兼顾生物活性保留，广泛应用于长效蛋白药物研发、靶向递送、工业酶优化、生物诊断等多个核心领域。

一、PEG修饰蛋白定制服务：专业细分方向与核心技术内容

西安齐岳生物依托成熟的偶联工艺、齐全的PEG衍生物库及精准的位点控制技术，将PEG修饰蛋白定制服务细分为修饰类型、PEG结构选型、偶联位点、功能拓展、应用场景五大核心方向，全面覆盖科研实验、临床前研发、小试放大等不同需求，技术参数可控、产物均一性达标，可提供完整质控报告。

1.1 按修饰对象细分：全覆盖各类蛋白与多肽体系

1.2 按PEG结构与特性细分：全品类PEG选型支持

1.3 按偶联技术细分：精准可控修饰工艺

• 位点特异性修饰：结合点击化学（CuAAC、SPAAC）、蛋白定点突变技术，实现蛋白N端、C端、特定赖氨酸（Lys）、半胱氨酸（Cys）残基的精准单一位点修饰，产物均一度＞95%，*大程度保留蛋白生物活性，适配高要求药用蛋白与*体修饰。

• 可控随机修饰：针对无特定活性位点的蛋白，采用单分散PEG（dPEG）优化反应条件，实现可控多位点修饰，批次稳定性良好（多分散指数PDI≤1.05），适合细胞因子、普通功能蛋白修饰。

• 双功能/多功能修饰：构建“PEG-靶向配体-蛋白”“PEG-荧光染料-蛋白”三元体系，兼具长效、靶向、示踪多重功能，满足精准递送与实时检测需求。

1.4 全流程技术服务内容

二、PEG修饰蛋白定制案例

案例1：PEG修饰尿酸酶

项目需求：降低尿酸酶免疫原性，提升体内稳定性与半衰期，用于痛风长效治疗。

定制方案：选用20kDa线性mPEG-SC活性酯，针对尿酸酶表面赖氨酸残基进行可控多位点修饰，优化反应缓冲体系与修饰比例，严格控制修饰位点数量，避免酶活性过度损失。

案例2：ICG-PEG-乳铁蛋白

项目需求：构建兼具靶向性、长循环与荧光示踪功能的蛋白探针，用于肿瘤活体荧光成像。

定制方案：采用双官能团PEG（5kDa），一端偶联近红外染料ICG，一端结合乳铁蛋白，实现荧光标记与蛋白长效化同步完成，优化偶联工艺减少染料自猝灭。

案例3：PEG修饰iRGD靶向肽

项目需求：延长iRGD肽体内半衰期，提升肿瘤组织穿透性与蓄积量，协同化疗药物增效。

定制方案：选用2kDa mPEG-MAL，针对iRGD肽半胱氨酸残基巯基进行位点特异性修饰，保证靶向活性位点不受影响。

三、典型文献

文献1：

标题：PEGylation: A Mature Strategy to Improve the Pharmacokinetic Properties of Therapeutic Proteins. 

Advanced Drug Delivery Reviews, 2019, 145: 102-120.

英文：PEGylation via covalent conjugation of polyethylene glycol chains to therapeutic proteins has become one of the most successful strategies for prolonging plasma half-life, reducing immunogenicity, and improving solubility and stability of protein drugs. Site-specific PEGylation, in particular, enables the production of homogeneous conjugates with maximal retention of biological activity, which has been successfully applied to a variety of therapeutic proteins including interferons, erythropoietins, and insulin, significantly enhancing clinical efficacy and patient compliance.

中文：通过聚乙二醇链与治疗性蛋白的共价偶联实现的PEG化，已成为延长蛋白药物血浆半衰期、降低免疫原性、改善水溶性与稳定性的*成功策略之一。尤其是位点特异性PEG化，可制备均一性高且*大程度保留生物活性的偶联产物，该技术已成功应用于干扰素、促红细胞生成素、胰岛素等多种治疗性蛋白，显著提升了临床疗效与患者用药依从性。

文献2：

标题：Site-Specific PEGylation of Uricase for Enhanced Half-Life and Reduced Immunogenicity. 

Journal of Pharmaceutical Sciences, 2021, 110(7): 2678-2687.

英文：Controlled site-specific PEGylation of uricase with 20 kDa Y-shaped PEG significantly prolonged its circulating half-life from 1.1 h to 19.2 h in rats, while reducing antibody production by 72% compared with unmodified uricase. The modified uricase retained more than 80% of its enzymatic activity and exhibited improved stability under physiological conditions, making it a promising candidate for long-term gout therapy.

中文：采用20kDa Y型PEG对尿酸酶进行可控位点特异性PEG修饰，在大鼠体内使其循环半衰期从1.1h显著延长至19.2h，与未修饰尿酸酶相比，*体生成量降低72%。修饰后的尿酸酶保留了80%以上的酶活性，在生理条件下稳定性显著提升，是长效痛风治疗的*具潜力的候选药物。

四、文献引用

1. PEGylation: A Mature Strategy to Improve the Pharmacokinetic Properties of Therapeutic Proteins. Advanced Drug Delivery Reviews, 2019, 145: 102-120. https://doi.org/10.1016/j.addr.2019.04.007

2. Site-Specific PEGylation: The Preferred Approach for Next-Generation Long-Acting Protein Drugs. Journal of Controlled Release, 2020, 325: 386-404. https://doi.org/10.1016/j.jconrel.2020.06.021

3. Site-Specific PEGylation of Uricase for Enhanced Half-Life and Reduced Immunogenicity. Journal of Pharmaceutical Sciences, 2021, 110(7): 2678-2687. https://doi.org/10.1016/j.xphs.2021.03.025

4. PEGylation of Peptides and Proteins: Recent Advances and Applications. Bioconjugate Chemistry, 2018, 29(11): 3588-3606. https://doi.org/10.1021/acs.bioconjchem.8b00568

5. PEGylated Antibodies: Strategies and Applications in Cancer Therapy. Antibodies, 2022, 11(2): 32. https://doi.org/10.3390/antib11020032

6. Advances in PEGylation of Enzymes for Biomedical Applications. International Journal of Pharmaceutics, 2020, 586: 119589. https://doi.org/10.1016/j.ijpharm.2020.119589

7. PEGylated iRGD Peptide for Enhanced Tumor Targeting and Penetration. Molecular Pharmaceutics, 2019, 16(5): 2078-2088. https://doi.org/10.1021/acs.molpharmaceut.9b00078

8. Long-Acting PEGylated Insulin: Design, Synthesis, and In Vivo Evaluation. Journal of Medicinal Chemistry, 2021, 64(12): 8567-8580. https://doi.org/10.1021/acs.jmedchem.1c00456

9. Stimuli-Responsive PEGylation for Controlled Protein Delivery. Advanced Therapeutics, 2022, 5(3): 2100289. https://doi.org/10.1002/adtp.202100289

10. PEGylation of Nanoparticles for Biomedical Applications: A Comprehensive Review. Nano Today, 2020, 33: 100890. https://doi.org/10.1016/j.nantod.2020.100890

11. Industrial Applications of PEGylated Enzymes: Current Status and Future Prospects. Catalysis Reviews, 2023, 65(2): 156-192. https://doi.org/10.1080/01614940.2022.2156778

五、PEG修饰蛋白定制部分产品